Brain Tumour Related Headache: Features, Pathophysiology and Management Strategies
DOI:
https://doi.org/10.12775/JEHS.2023.20.01.020Keywords
Brain Tumour, Headache, Therapy, Surgery, Radiotherapy, PharmacotherapyAbstract
Introduction. Brain tumours constitute approximately 1% of all newly diagnosed cancers. Their manifestation typically involves headache, neurological impairment, focal onset seizures and syndromes related to tumour location. Severe headache presents as a prevailing symptom and occurs in over 50% of patients. Brain tumour associated headache exerts significant effect on quality of life in cancer patients. The following article aims to provide a comprehensive overview of most common and promising brain tumour related headache treatment strategies.
State of knowledge. Headache in brain tumour patients arises from traction or displacement of intracranial pain-sensitive structures, such as vascular tissue, dura mater or periosteum. This can be caused by tumour’s mass itself, by tumour associated oedema or as a sequela of anti-tumour treatment. Most common therapeutic modalities include tumour surgical resection, cerebral oedema management, radiotherapeutic interventions and administration of analgesic agents. Complete removal of the tumour stands as the most effective approach, often bringing substantial alleviation in majority of cases.
Conclusion. Headache affects the majority of individuals afflicted by brain tumours. Not all patients are suitable candidates for the resection of the underlying neoplasm. In such instances, the application of alternative approaches might be beneficial. Ongoing and future investigations may enhance the development of novel treatment strategies, possibly influencing the well-being of cancer patients, especially within palliative care area.
References
Ostrom, Q.T., et al., CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol, 2017. 19(suppl_5): p. v1-v88.
Siegel, R.L., K.D. Miller, and A. Jemal, Cancer Statistics, 2017. CA Cancer J Clin, 2017. 67(1): p. 7-30.
Louis, D.N., et al., The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol, 2016. 131(6): p. 803-20.
Barnholtz-Sloan, J.S., Q.T. Ostrom, and D. Cote, Epidemiology of Brain Tumors. Neurol Clin, 2018. 36(3): p. 395-419.
Hadidchi, S., et al., Headache and Brain Tumor. Neuroimaging Clin N Am, 2019. 29(2): p. 291-300.
Forsyth, P.A. and J.B. Posner, Headaches in patients with brain tumors: a study of 111 patients. Neurology, 1993. 43(9): p. 1678-83.
Purdy, R.A. and S. Kirby, Headaches and brain tumors. Neurol Clin, 2004. 22(1): p. 39-53.
Boiardi, A., et al., Headache in brain tumours: a symptom to reappraise critically. Neurol Sci, 2004. 25 Suppl 3: p. S143-7.
Kunkle, E.C., B.S. Ray, and H.G. Wolff, Studies on Headache: The Mechanisms and Significance of the Headache Associated with Brain Tumor. Bull N Y Acad Med, 1942. 18(6): p. 400-22.
Levy, M.J., The association of pituitary tumors and headache. Curr Neurol Neurosci Rep, 2011. 11(2): p. 164-70.
Levy, M.J., M.S. Matharu, and P.J. Goadsby, Prolactinomas, dopamine agonists and headache: two case reports. Eur J Neurol, 2003. 10(2): p. 169-73.
Loghin, M. and V.A. Levin, Headache related to brain tumors. Curr Treat Options Neurol, 2006. 8(1): p. 21-32.
Pfund, Z., et al., Headache in intracranial tumors. Cephalalgia, 1999. 19(9): p. 787-90; discussion 765.
Middleton, M.R., et al., Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol, 2000. 18(1): p. 158-66.
Yung, W.K., et al., A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer, 2000. 83(5): p. 588-93.
Einhorn, L.H., et al., Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy. J Clin Oncol, 1990. 8(4): p. 731-5.
Kaal, E.C. and C.J. Vecht, The management of brain edema in brain tumors. Curr Opin Oncol, 2004. 16(6): p. 593-600.
Kahn, K. and A. Finkel, It IS a tumor -- current review of headache and brain tumor. Curr Pain Headache Rep, 2014. 18(6): p. 421.
Pace, A., et al., European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. Lancet Oncol, 2017. 18(6): p. e330-e340.
Yamada, K., et al., Effects of steroids on the blood–brain barrier. 1989. 2: p. 53-76.
Portnow, J., et al., A cyclooxygenase-2 (COX-2) inhibitor compared with dexamethasone in a survival study of rats with intracerebral 9L gliosarcomas. Neuro Oncol, 2002. 4(1): p. 22-5.
Tjuvajev, J., et al., Anti-neoplastic properties of human corticotropin releasing factor: involvement of the nitric oxide pathway. In Vivo, 1998. 12(1): p. 1-10.
Zangari, M., et al., Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res, 2004. 10(1 Pt 1): p. 88-95.
The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia, 2013. 33(9): p. 629-808.
Valentinis, L., et al., Headache attributed to intracranial tumours: a prospective cohort study. Cephalalgia, 2010. 30(4): p. 389-98.
Ravn Munkvold, B.K., et al., Preoperative and Postoperative Headache in Patients with Intracranial Tumors. World Neurosurg, 2018. 115: p. e322-30.
Gee, J.R., Y. Ishaq, and N. Vijayan, Postcraniotomy headache. Headache, 2003. 43(3): p. 276-8.
Ansari, S.F., C. Terry, and A.A. Cohen-Gadol, Surgery for vestibular schwannomas: a systematic review of complications by approach. Neurosurg Focus, 2012. 33(3): p. E14.
Rimaaja, T., et al., Headaches after acoustic neuroma surgery. Cephalalgia, 2007. 27(10): p. 1128-35.
Ryzenman, J.M., M.L. Pensak, and J.M. Tew, Jr., Headache: a quality of life analysis in a cohort of 1,657 patients undergoing acoustic neuroma surgery, results from the acoustic neuroma association. Laryngoscope, 2005. 115(4): p. 703-11.
Bello, C., et al., Postcraniotomy Headache: Etiologies and Treatments. Curr Pain Headache Rep, 2022. 26(5): p. 357-364.
Nigim, F., J.F. Critchlow, and E.M. Kasper, Role of ventriculoperitoneal shunting in patients with neoplasms of the central nervous system: An analysis of 59 cases. Mol Clin Oncol, 2015. 3(6): p. 1381-6.
Coia, L.R., The role of radiation therapy in the treatment of brain metastases. Int J Radiat Oncol Biol Phys, 1992. 23(1): p. 229-38.
Borgelt, B., et al., The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys, 1980. 6(1): p. 1-9.
Hoskin, P.J., J. Crow, and H.T. Ford, The influence of extent and local management on the outcome of radiotherapy for brain metastases. Int J Radiat Oncol Biol Phys, 1990. 19(1): p. 111-5.
Khuntia, D., et al., Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol, 2006. 24(8): p. 1295-304.
Niranjan, A., et al., Guidelines for Multiple Brain Metastases Radiosurgery. Prog Neurol Surg, 2019. 34: p. 100-109.
Verhaak, E., et al., Health-related quality of life in adult patients with brain metastases after stereotactic radiosurgery: a systematic, narrative review. Support Care Cancer, 2020. 28(2): p. 473-484.
King, S., et al., A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliat Med, 2011. 25(5): p. 525-52.
Perloff, M.D., Practical considerations in opioid use for brain neoplasm. Continuum (Minneap Minn), 2015. 21(2 Neuro-oncology): p. 480-6.
Ball, M., et al., Renal failure and the use of morphine in intensive care. Lancet, 1985. 1(8432): p. 784-6.
Chandok, N. and K.D. Watt, Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc, 2010. 85(5): p. 451-8.
Fischer, B. and E. Argento, Prescription opioid related misuse, harms, diversion and interventions in Canada: a review. Pain Physician, 2012. 15(3 Suppl): p. Es191-203.
Khasabova, I.A., et al., Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. J Neurosci, 2012. 32(20): p. 7091-101.
Manzanares, J., M. Julian, and A. Carrascosa, Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol, 2006. 4(3): p. 239-57.
Ellert-Miklaszewska, A., et al., Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. Brain Res, 2007. 1137(1): p. 161-9.
Hryhorowicz, S., et al., Pharmacogenetics of Cannabinoids. Eur J Drug Metab Pharmacokinet, 2018. 43(1): p. 1-12.
Kaminska, B. and A. Ellert-Miklaszewska, Cannabinoid signalling in glioma cells. Springerplus, 2015. 4(Suppl 1): p. L11.
Vučković, S., et al., Cannabinoids and Pain: New Insights From Old Molecules. Front Pharmacol, 2018. 9: p. 1259.
Whiting, P.F., et al., Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. Jama, 2015. 313(24): p. 2456-73.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Patrycja Doruch, Michał Senger, Karolina Rogacka-Pyrak, Kornelia Kędziora-Kornatowska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 324
Number of citations: 0